期刊文献+

HPLC测定N-(N-苯甲酰基-O-苯甲酰基-L-酪氨酰基)-L-苯丙氨醇及其三种杂质 被引量:2

Determination of N-(N-benzoyl-O-benzoyl-L-tyrosyl)-L-phenylalaninol and Three Impurities by HPLC/MS
原文传递
导出
摘要 建立了Y101中间体N-(N-苯甲酰基-O-苯甲酰基-L-酪氨酰基)-L-苯丙氨醇(M057)及其已知杂质的含量测定方法。采用液相色谱质谱联用技术(HPLC/MS),正离子扫描模式指认杂质峰;采用高效液相色谱(HPLC)外标法,以甲醇-水(v∶v=75∶25)洗脱,测定M057含量,以甲醇-0.01%磷酸水溶液梯度洗脱,测定3个已知杂质含量。测定结果:M057含量不低于77%,已知杂质总量未超过4.5%。本法已作为该中间体质量内控方法。 N-(N-Benzoyl-O-benzoyl-L-tyrosyl)-L-phenylalaninol (M057), an intermediate for dipeptide Y101, and three impurities co-existed with M057 were determined with HPLC/MS. The positive ion scanning was used for the identification of the impurities and their contents were determined using methanol -0.01% phosphoric acid as the gradient elution. An external standard was used for the analysis of M057 with methanol-water (v:v=75:25) as the mobile phase. This method has been used as a standard for the quality control of M057.
出处 《精细化工中间体》 CAS 2014年第2期65-69,共5页 Fine Chemical Intermediates
基金 "十二五"国家重大新药创制科技重大专项(2011ZX09102-009-002) 贵州省中药现代化科技产业研究开发专项(黔科合中药字[2012]5054)
关键词 HPLC MS N-(N-苯甲酰基-O-苯甲酰基-L-酪氨酰基)-L-苯丙氨醇 杂质 HPLC/MS N-(N-benzoyl-O-benzoyl-L-tyrosyl)-L-phenylalaninol impurities
  • 相关文献

参考文献4

二级参考文献38

  • 1赵玲,郭继芬,张爱军,赵毅民.利用LC-MS/MS法快速鉴定盐酸头孢吡肟中的同分异构体杂质[J].药学学报,2005,40(4):361-364. 被引量:9
  • 2包俊 冉懋雄 陆科闵 等.贵州苗族医药研究与开发[M].贵阳:贵州科技出版社,1999.200.
  • 3贵州省卫生厅.“贵州省药品标准”1994年版,贵阳,1994.25
  • 4Junichi Kitajima, Nobuyuki Suzuki,Toru ishikawa, et al. New hemiterpenoid pentol and monoterpenoid glycoside of Torillis japonica fruit, and consideration of the origin of apiose. Chemical and Pharmaceutical Bullin, 1998,46(10):1583~1586
  • 5Hirozi Suzuki, Tsutomu Ikeda, Takashi Matsumoto, et al.Polyphenol components in culured cells of amaeha(Hydrangea macrophylla Seringe var. Thunbergii Makino). Agric Biol Chem, 1978,42(6):1133~1137
  • 6Pang R,Tao JY,Zhang SL,ef al. In vitro antiviral activity of lute-in against hepatitis B virus [ J]. Phyiother Res,2010,24 (11):1627-1 630.
  • 7Lin KW,Kirchner JT. Information from your family doctor:hepati-tis B infection [ J ]. Am Farn Physician ,2004,69 (1) :86.
  • 8Park N,Song I,Chung Y. Chronic hepatitis B in hepatocarcino-genesis[ J] ? Postgrad Med 7,2006,82(970) :507 -515.
  • 9Karayiannis P. Current therapies for chronic hepatitis B virus in-fection[ J]. Expert Rev Anti Infect 77ier,2004,2(5) :745 -760.
  • 10Fattovich G,Brollo L,Giustina G,et al. Natural-history and prog-nostic factors for chronic hepatitis type B[ J]. Gul,1991,32(3);294 -298.

共引文献49

同被引文献12

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部